08:05 – 08:05: Welcome
08:05 – 08:20: Clinical Trial Shaping Our Next Step – Partnership between Investigators and Patients - Karen Kelly
08:20 – 08:30: Electronic Cigarettes and Vaping - Anthony Alberg
08:30 – 08:45: Imaging to Identify and Characterize Lung Nodules - Herbert MacMahon
08:45 – 08:55: Molecular Biomarkers in Early Detection of Lung Cancer - Peter Mazzone
08:55 – 09:05: How Lung Cancer Advocacy and Research Has Changed in the Past Years - Jill Feldman
09:05 – 09:15: The Increasing Importance of Social Media in Advocacy - Brendon Stiles
09:15 – 09:25: Financial Toxicity of Cancer Therapy - Fumiko Chino
09:25 – 09:45: Panel Discussion with all Speakers

10:15 – 10:20: Introduction - Charu Aggarwal
10:20 – 10:30: Innovations in Broad Sequencing Including Fusion Detection and Cellularity Constraints - Marc Ladanyi
10:30 – 10:40: TMB Ready for Prime Time? - John Longshore
10:40 – 10:50: Incorporating Blood Biomarkers into Clinical Practice - Charu Aggarwal
10:50 – 11:00: Genomic Biomarkers of Immunotherapy Sensitivity and Resistance - Ferdinandos Skoulidis
11:00 – 11:15: Panel Discussion

10:15 - 10:20: Introduction - Jessica Donington
10:20 – 10:28: Pre-habilitation/Patient Selection and Enhanced Recovery after Surgery (ERAS) - Katherine Kuhns
10:28 – 10:36: Induction Strategies for Stage II/IIIA NSCLC Including Radiation and IO - Jessica Donington
10:36 – 10:44: Role of IO and SBRT for Inoperable Early Stage NSCLC - Cliff Robinson
10:44 – 10:52: Recurrence after SBRT - Mara Antonoff
10:52 – 11:00: Assessment and Management of IO Toxicity in Combined Modality Trials - Mary Jo Fidler
11:00 – 11:15: Panel Discussion

12:45 – 12:50: Introduction - Evertt Vokes
12:50 – 13:35: NCI Perspectives: Lung Cancer Initiatives - Douglas R. Lowy, NCI Acting Director
13:35 – 13:45: Q&A

14:00 – 14:07: Pembrolizumab Plus Chemotherapy For Advanced NSCLC Without Tumor PD-L1 Expression: Pooled Analysis of KN021G, KN189 and KN407 – Hossein Borghaei
14:07 – 14:14: Prognostic Value of Baseline Autoantibodies in Metastatic NSCLC Patients Receiving PD-/PDL-1 Targeted Immunotherapy – Imad Tarhoni 14:14 – 14:21: Prognostic Role of NLR in Stage III NSCLC Undergoing Chemoradiation: Secondary Analysis of PROCLAIM trial – Tithi Biswas
14:21 – 14:28: Safety and Efficacy of Flu Vaccination after Treatment with Immune Checkpoint Inhibitors: A Retrospective Review – Nathan Roberts
14:28 – 14:38: Discussant: IO Prognostics Beyond PD-L1 and TMB – Nasser Hanna
14:38 – 14:43: Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer – Bob Li
14:43 – 14:48: Capmatinib (INC280) in METΔex14-mutated advanced NSCLC: efficacy data from the phase 2 GEOMETRY mono-1 study – Rebecca S. Heist
14:48 – 14:53: A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRm+/T790M+ Advanced or Recurrent NSCLC Patients – Yuankai Shi
14:53 – 15:03: Discussant – Jyoti Patel
15:03 – 15:13: Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer – Matthew Smeltzer
15:13 – 15:23: Discussant: NGS Path Forward with IASLC – Heather Wakelee
15:23 – 15:30: Q&A

15:45 – 15:55: Discussant: Practice Patterns: So Many Choices and Optimal Therapies – Kurt Oettel
• Oncologists’ Management of Advanced NSCLC: A Simulation-Based Performance Assessment – Lori Pender
• Changes in Immune Checkpoints Landscape Associated with TGF-β induced EMT in Lung Adenocarcinoma – Hita Moudgalya
• CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC – David R. Spigel
• CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients – Bruce E. Johnson
• CANOPY-2: Phase 3 Study of Canakinumab plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC – Bijoyesh Mookerjee

15:55 – 16:05: Discussant: Novel Risk Prediction Strategies – Joel Neal
• Incidence and Predictors Associated with the Development of Peripheral Neuropathy in Non-Small Cell Lung Cancer Patients - Jerzy Tyczynski
• Incidence and Predictors Associated with the Development of Pneumonitis In Non-Small Cell Lung Cancer Patients. – Jerzy Tyczynsk
• Diagnostic Non-Invasive Biopsy Can Substitute Conventional Tissue Dependent Procedures in Suspected Cases of Lung Cancer - Dadasaheb Akolkar
• Artificial Intelligence Can Detect Lung Cancer from High Resolution Microscopic Images of Conditioned Peripheral Blood – Dadasaheb Akolkar

16:05 – 16:15: Discussant: Radiation in 2020 and Beyond – Kenneth Rosenzweig
• Stereotactic Modulating Radiation Therapy (SMRT) for Oligo-Metastatic Non-Small Cell Lung Cancer - Joseph R. Kelley
• Targeting the Chemoradiation Resistance of Lung Cancers with KRAS/TP53 Co-mutations - Henning Willers
• Raman Spectroscopy and NIR Spectroscopy as Possible Aid in Localisation of Solitary Pulmonary Nodules - Jiri Votruba

16:15 – 16:25: Discussant: Quality Lung Cancer Care – Tim Kruser
• Successful Implementation of a Free Lung Cancer Screening Program in a Rural Tertiary Care Hospital Setting - Michael J. Minarich
• Beneficial Effect of Antibiotic Use in Patients with Stage IV NSCLC Treated with Immune Checkpoint Inhibitors - Chao Huang
• Lung Cancer Strategist Program: A Novel Care Delivery Model to Improve Timeliness of Diagnosis and Treatment - William W Phillips
• Medicaid Outcome Inequalities in Small Cell Lung Cancer – Stephen Chun

16:25 – 16:45: Q&A

• Clinical Application of Plasma miR-34b-3p and miR-302a-5p in the Diagnosis of Non-Small Cell Lung Cancer – Yang Liu
• Socio-Demographic Characteristics and Perception of Tobacco Work and Hazards in a Rural Community of Nigeria – Ofonakara Uzochukwu
• Chemotherapy with VMAT (Volumetric Modulated Arc Therapy) Radiation Therapy for Poor Risk-Stage IIIA-C NSCLC Patients – Yu Zhou
• Survival Benefit of Surgically Resected Occult N2 (c-N0,1 and p-N2) Non-Small-Cell Lung Cancer – Masahiko Harada
• Combined Effects of HDAC Inhibitor and Metalloproteinase Inhibitor on Invasion and Growth of Non-Small Cell Lung Cancer – Yu Zhang
• Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on Anti-PD-1 Therapy – Megan Randall
• An Overview of Lung and Breast Cancer Using the National Cancer Database – Leigh Deshotels
• External Peer Review of the Western New South Wales Lung Cancer Service – A Unique Regional and Rural Australian Experience – Sugamya Mallawathantri
• Immunophenotyping of CD 146 Expression T cells in Lung Cancer Patients – Ayobami Olajuyin
• Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation in NSCLC – Davide Brocco
• Inflammatory Signature Difference in Rural Urban and Regional Occupational Exposure in Lung Cancer – Nitika Sharma
• Post-PACIFIC Trial Era: Patterns of Outcomes and Toxicities from a Single Private Institution in a Developing Country – Daniel Przybysz
• Demographics and Survival in Malignant Pleural Mesothelioma: Analysis of SEER Data – Nwabundo Anusim
• Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma – Idrees Mian
• Immune Profiling Data and Mutational Status Improves Prediction of Risk of Death in Non-Small Cell Lung Carcinoma – Edwin Parra
• The Presence of Secondary Follicles in Early Stage Lung Adenocarcinoma Reflects Disease Burden – Rebecca Obeng
• A Study on Clinicopathological Features and Diagnostic Methods of ALK Fusion-Positive Non-Small Cell Lung Cancer in Korea – Bong Kyung Shin
• Lung Adenocarcinoma Harboring EGFR Exon18 Variant and MET Exon14 Mutation Responsive to Treatment with Afatinib and Crizotinib – Max He
• Comparison of Genetic Profiles of Pulmonary Sarcomatoid Carcinoma (PSC) Between Asian and Western Populations – Yijia Guo
• MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer – Dan Yan
• Lung Cancer Screening Initiative and Identification of Novel Blood Biomarkers for Early Detection of Lung Cancer – Shreya Deb
• Metabolic Responses to Metformin in Early-Stage NSCLC Treated with Definitive Radiotherapy: Results of a Phase II Trial – Stephen Chun
• RNA pathway Enrichment in Serum Based Mass Spectroscopy Prognostic Analyses – Mary Fidler
• The Lung Microbiome and Metabolome are Altered in Lung Cancer Patients – Frank Weinberg

08:15 – 08:18: Introduction - Lecia Sequist
08:18 – 08:25: Treatment of New and Emerging Driver Mutations - Paul Paik
08:25 – 08:32: Updates in ALK - Caroline McCoach
08:32 – 08:39: Progression after First Line Osimertinib - Lecia Sequist
08:39 – 08:46: Clinical Trials in MPM - Hedy Lee Kindler
08:46 – 08:52: SCLC – Updates - Anna Farago
08:52 – 09:00: CNS Disease- Systemic Therapy as First Line – From a Radiation Oncology Perspective - Vinai Gondi
09:00 – 09:15: Panel Discussion

08:15 – 08:20: Introduction
08:20 – 08:28: Rebiopsy after Progressive Disease, Pseudoprogression, Adjudication of Site Selection - Tim Murgu
08:28 – 08:35: Management of Malignant Effusion (TKIs and IO) - Carla Lamb
08:35 – 08:43: MPR Post Neo-adjuvant IO - Ignacio Wistuba
08:43 – 08:51: Diagnostic and Management Dilemmas in Synchronous NSCLC - Elizabeth David
08:51 – 08:59: Ablative Radiation Therapy for Operable Disease - Megan Daly
08:59 – 09:15: Panel Discussion

09:45 – 09:52: Outcomes of Integrating Individualized Tobacco Cessation Counseling in a Lung Cancer Screening Program – John Pagteilan
09:52 – 09:59: Outcomes of Smoking Cessation Counseling in a Surgical Clinic – Nicholas Tingquist
09:59 – 10:06: CNS Metastasis as Exclusion Criteria in Clinical Trials Involving Extensive-Stage Small Cell Lung Cancer – Takefumi Komiya
10:06 – 10:16: Discussant: Smoking Cessation and Inclusivity in Clinical Trials – Ticiana Leal
10:16 – 10:26: Clinical-Radiomic Models Predict Overall Survival Among Non-Small Cell Lung Cancer Patients Treated with Immunotherapy - Ilke Tunali
10:26 – 10:33: Lung Cancer Screening in Patients with versus Without a Personal History of Cancer – Patricia Rivera
10:33 – 10:40: Low Dose CT Lung Screening in First Responders – Vershalee Shukla
10:40 – 10:47: Peritumoral and Intratumoral Radiomic Features Identify Aggressive Screen-Detected Early-Stage Lung Cancers – Jaileene Perez Morales
10:47 – 10:54: Multi-Planar Lung Cancer Measurements Provide Improved Accuracy in Clinical Staging – Erin M. Corsini
10:54 – 11:04: Discussant: Radiomics, Screening and Imaging - Sharyn Katz

09:45 – 09:52: Biomarkers of Autoimmune Toxicity in Metastatic SCLC Patients Receiving PD-1/PDL-1 Targeted Therapy – Apoorva Tangri
09:52 – 09:59: Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with Brain Metastases Treated with Pembrolizumab – Lova Sun
09:59 – 10:06: Multi-institutional Study of Pneumonitis after Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer – Timothy Sita
10:06 – 10:13: Analysis of Patient Microbiome and its Correlation to Immunotherapy Response and Toxicity in Lung Cancer – Jun Zhang
10:13 – 10:23: Discussant: Predictors of IO Toxicity – Kristen Marrone
10:23 – 10:30: Impact of an EGFR-Lung Cancer Diagnosis on Quality of Life of Patients: Learnings from Project PRIORITY – Jill Feldman
10:30 – 10:37: Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer – Jacqueline Aredo
10:37 – 10:44: Clinical Utility of ctDNA Driver Genomic Alterations (GA) Directing Targeted Therapy in Untreated Advanced NSCLC Patients – Benjamin Besse
10:44 – 10:51: Overall Survival in Patients with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: An Update of the GioTag Study – Christoph Weinlinger
10:51 – 11:01: Discussant: Targeted Therapies: Partnerships, Inequities, and Best Therapies – Christine Lovly

11:30 – 11:45: Novel Tumor Biomarkers and Tumor Immune Profiling - Kurt Schalper
11:45 – 12:00: Microbiome and Implications for Response to IO - Thomas Gajewski
12:00 – 12:15: Treatment of Oligometastatic Disease Denovo and at Progression with Driver Mutations, on IO or Neither - Puneeth Iyengar and Luda Bazhenova
12:15 – 12:30: Closing Remarks

A Unscripted Life: Using Improvisational Theater Techniques to Help Women In Medicine Claim Power, Collaborate and Communicate – Katie Watson